ライフサイエンスコーパス: psychotropic

1 morbidity was associated with greater use of psychotropics.

2 beta blockers, calcium channel blockers, or psychotropics.

3 only, and 2% opioids with coprescription of psychotropics.

4 c and anti-inflammatory activity without the psychotropic action of THC.

5 her experimental studies to understand their psychotropic action.

6 finding that salvinorin A exerts its potent psychotropic actions through the activation of opioid re

7 cid diethylamide are thought to elicit their psychotropic actions via serotonin receptors of the 5-hy

8 ine has important anesthetic, analgesic, and psychotropic actions.

9 ins such as ergot alkaloids that have potent psychotropic activity.

10 noid levels and action, which exhibit little psychotropic activity.

11 1A)) receptors, may represent a new class of psychotropic agent for the treatment of psychosis in sch

12 ogical intervention with SEP-363856, a novel psychotropic agent with agonism at trace amine receptor

13 s (13 trials), prokinetic agents (6 trials), psychotropic agents (7 trials), and loperamide (4 trials

14 otics (n=22), antidepressants (n=202), or no psychotropic agents (n=85).

15 Psychotropic agents act on a variety of neurotransmitter

16 Ethanol is one of the most widespread psychotropic agents in western society.

17 Evidence for use of psychotropic agents is inconclusive; more high-quality t

18 not increased when patients were assigned to psychotropic agents rather than placebo except for heter

19 s can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprote

20 Although psychotropic agents were shown to produce global improve

21 The role of psychotropic agents, especially tricyclic antidepressant

22 urthermore, 3- to 4-month exposure to modern psychotropic agents, such as atypical antipsychotic agen

23 gs, notably clozapine, as well as some other psychotropic agents.

24 ive hepatitis C status who were taking other psychotropic agents.

25 of the endogenous counterpart of marijuana's psychotropic and appetite-inducing component Delta(9)-te

26 cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millenni

27 etabolites may prolong the parent compound's psychotropic and physiological effects and may contribut

28 etabolites may prolong the parent compound's psychotropic and physiological effects and may contribut

29 nt pain therapeutics suffer from undesirable psychotropic and sedative side effects, as well as abuse

30 ccurrence of Salmonella, Escherichia coli or psychotropic bacteria.

31 nce exists to support the use of alternative psychotropic classes (e.g., antidepressants, anticonvuls

32 The main psychotropic component in marijuana, Delta(9)-tetrahydro

33 acute 20-min exposure to two commonly abused psychotropic compounds, Delta(9)-tetrahydrocannabinol (T

34 pioid prescription without coprescription of psychotropics decreased from 11.9% to 8.4%, and opioids

35 , and that the neuroprotective effect of the psychotropic Delta9-tetrahydroxycannabinol (THC) or nonp

36 ase in the proportion of existing users with psychotropic dose increases in the weeks after the attac

37 nes may influence phenotypes associated with psychotropic drug administration.

38 Psychotropic drug costs increased during the first year

39 the potentially confounding effects of prior psychotropic drug exposure.

40 had not received any sedation, narcotic, or psychotropic drug in the previous 24 hrs.

41 -HT(2C) receptors in motivated behaviors and psychotropic drug mechanisms.

42 Using this approach, we identified the psychotropic drug pimozide as a STAT5 inhibitor.

43 ent with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients w

44 pect of identifying biological predictors of psychotropic drug response and could provide the means o

45 nitial research into the pharmacogenetics of psychotropic drug response suggests that specific genes

46 rst generation of pharmacogenetic studies of psychotropic drug response, and consider future directio

47 el method of dissecting the heterogeneity of psychotropic drug response.

48 Glycine or D-cycloserine augmentation of psychotropic drug treatment each improved psychotic and

49 -methyl-D-aspartate receptor augmentation of psychotropic drug treatment in these two individuals.

50 Although sex differences occur with some psychotropic drug treatments, they are not well defined

51 bid personality disorder (1.24 [1.11-1.39]), psychotropic drug use (antipsychotics 1.51 [1.35-1.69],

52 Psychotropic drug use was lower among African Americans

53 parents' report of neurologic complications, psychotropic drug use, and special education.

54 Surprisingly, another psychotropic drug, phencyclidine, displayed a selective

55 ripheral OE can serve as a proxy for certain psychotropic drug-induced actions on SVZ brain cell prol

56 These results show that psychotropic drug-induced cell proliferation occurs in t

57 sonance imaging studies were conducted in 21 psychotropic drug-naive children, aged 8 to 17 years, wi

58 n severity on the CY-BOCS in the subgroup of psychotropic drug-naive patients.

59 MRI examinations of 37 psychotropic drug-naive pediatric OCD patients and 26 ag

60 ous 1.5-mm magnetic resonance images from 23 psychotropic drug-naive pediatric patients with OCD (sev

61 ry to examine brain structure, especially in psychotropic drug-naive pediatric patients.

62 re (OR, 4.99; 95% CI, 1.16 to 21.38) or with psychotropic drugs (OR, 2.78; 95% CI, 1.10 to 7.01).

63 tric outpatients taking weight gain-inducing psychotropic drugs (sample 1, n = 152).

64 e intracellular chaperone proteins that bind psychotropic drugs and also clinically used drugs such a

65 Although interactions between psychotropic drugs and contraceptives are rare, clozapin

66 ard and dependence, brain trauma and injury, psychotropic drugs and pain using small animals.

67 of therapies should be used, and the use of psychotropic drugs and psychological treatment alternati

68 ectrocardiogram in pediatric patients taking psychotropic drugs and recommendations for monitoring th

69 widely; they bind diverse ligands, including psychotropic drugs and steroids, regulate many ion chann

70 ng in zebrafish to discover and characterize psychotropic drugs and to dissect the pharmacology of co

71 Treatment patterns for psychotropic drugs appear to have remained stable over t

72 pensity substantially increase when specific psychotropic drugs are administered to patients with hyp

73 The authors examined how the use of psychotropic drugs has shifted over the course of 10 yea

74 Many specific psychotropic drugs have been reported to prolong the QTc

75 Therapeutic outcomes from several psychotropic drugs have been weakly linked to specific g

76 death in pediatric patients taking selected psychotropic drugs have raised the possibility of ventri

77 The use of psychotropic drugs in clinical and translational brain r

78 The use of psychotropic drugs in the pediatric population has incre

79 yping and screening of genetic mutations and psychotropic drugs in zebrafish (Danio rerio).

80 , address this question and demonstrate that psychotropic drugs modify specific methyl-CpG-binding pr

81 -blind, placebo-controlled trial (Effects of Psychotropic Drugs on Developing Brain-Methylphenidate)

82 t mediates the modulation of ion channels by psychotropic drugs through a unique transduction mechani

83 atient care was 4.2%, and for treatment with psychotropic drugs was 32.3%.

84 The major classes of psychotropic drugs were introduced in an extraordinary d

85 77 [95% CI, 1.72 to 4.44] for treatment with psychotropic drugs).

86 Psychotropic drugs, 5-hydroxytryptamine (5-HT)-receptor

87 hat bind certain steroids, neuroleptics, and psychotropic drugs, form a trimeric complex with ankyrin

88 g-term adaptations underlying the effects of psychotropic drugs, including the actions of antidepress

89 ric conditions, and concomitant use of other psychotropic drugs, risk of suicide death was 2.7 times

90 cognition, and addiction and is regulated by psychotropic drugs, stress, and corticosteroids.

91 protein (CREB) in the adaptive responses to psychotropic drugs, we have developed inducible, brain r

92 ad substitution of antipsychotics with other psychotropic drugs.

93 peutic actions as well as adverse effects of psychotropic drugs.

94 ar dysrhythmias in pediatric patients taking psychotropic drugs.

95 chiatric patients and the effects of various psychotropic drugs.

96 -tetrahydrocannabivarin, which are devoid of psychotropic effects and possess potent anti-inflammator

97 Endocannabinoid (EC) signaling mediates psychotropic effects and regulates appetite.

98 HU-320 administration yielded no adverse psychotropic effects in mice.

99 ratory behavior and suggest that some of the psychotropic effects of LSD may be mediated by 5-HT5A re

100 tes have been suggested to contribute to the psychotropic effects of the cannabinoids; however, the m

101 rious pathologies while avoiding the adverse psychotropic effects that can accompany CB1 receptor-bas

102 of biological effects ranging from transient psychotropic effects to prolonged medicinal benefits, ma

103 ng cannabinoid agonists are known to produce psychotropic effects, it has been suggested that the CB1

104 Also, because CB2 agonists lack psychotropic effects, they may serve as novel anticancer

105 a is one of the most abused drugs due to its psychotropic effects.

106 )) agonists are potential analgesics void of psychotropic effects.

107 cretion on mood regulation and the potential psychotropic efficacy of androgen replacement in men are

108 ive performance, comorbidities, impulsivity, psychotropic exposure, and possible brain damage from at

109 exposure, compared with antidepressant or no psychotropic exposure, was associated with significantly

110 among those with and without prescription of psychotropics, from 2011 to 2015.

111 nd decrease the plasma concentration of many psychotropic, immunosuppressant, antineoplastic, antimic

112 Use of psychotropics in general, and antidepressants in particu

113 Subjects consisted of 68 psychotropic (including stimulant)-naive and smoking-nai

114 tions (opioid pain medications and nonopioid psychotropics, including antidepressants/anxiolytics and

115 k relative to no treatment or an alternative psychotropic is unclear.

116 those with antidepressant (mean=68.57) or no psychotropic (mean=71.19) exposure, after controlling fo

117 oms were more likely to have been prescribed psychotropic medication (adjusted odds ratio = 1.9; 95%,

118 nary frequency or leaking (P = .006), use of psychotropic medication (P = .009), and denial of life a

119 .058), and 21 patients stopped or decreased psychotropic medication (z = -2.887, p = .004).

120 s before the cancer death/index date, use of psychotropic medication 6 months before the cancer death

121 ehavior disorders as well as nonadherence to psychotropic medication and lower socioeconomic levels.

122 Use of psychotropic medication and presence of comorbid major d

123 both relative to patients not receiving any psychotropic medication and relative to their pretreatme

124 effect persisted after covarying for current psychotropic medication and severity of current depressi

125 ated the relative mortality, prescription of psychotropic medication and use of primary medical care

126 sions to terminate a pregnancy if prescribed psychotropic medication during early pregnancy than if n

127 Opioids are frequently coprescribed with psychotropic medication during pregnancy and are associa

128 otic symptoms (47.6%) had taken a prescribed psychotropic medication during the last month.

129 onth), 4.1% of whom had a prescription for a psychotropic medication during the study period.

130 Psychotropic medication exposure has been shown to alter

131 re present early in life, are not related to psychotropic medication exposure, and are sex specific.

132 dedness-, and education-matched HCs, free of psychotropic medication for at least 12 weeks, viewed 60

133 All subjects had been free of psychotropic medication for at least 4 weeks.

134 The data supporting concomitant psychotropic medication for youths are almost exclusivel

135 dentify available information on concomitant psychotropic medication for youths.

136 o the prevalence and patterns of concomitant psychotropic medication given to youths with emotional a

137 elements of detailed first-episode-specific psychotropic medication guidelines and a computerized de

138 % reported that they had been treated with a psychotropic medication in the past 12 months.

139 harmacodynamics, and side-effect profiles of psychotropic medication in this population.

140 95% CI=0.59-0.90) declined while use of only psychotropic medication increased (44.1% and 57.4%; adju

141 ctual disability have behaviour problems and psychotropic medication is a commonly used management st

142 When psychotropic medication is used during breast-feeding, i

143 but few studies, that examine the effect of psychotropic medication on anxiety disorders in children

144 e-blind placebo-controlled trial (Effects of Psychotropic Medication on Brain Development-Methylpheni

145 Psychotropic medication polypharmacy is common in psychi

146 Longitudinal Neuropsychiatric Inventory and psychotropic medication prescription data from neuropath

147 3 months, falls, fall-related fractures, and psychotropic medication prescriptions.

148 rences in falls, fall-related fractures, and psychotropic medication prescriptions.

149 36 healthy control (HC) participants free of psychotropic medication recruited from several psychiatr

150 altered eating behavior, or side effects of psychotropic medication remains unclear.

151 % CI=0.48-0.90) as well as psychotherapy and psychotropic medication together (40.0% and 32.1%; adjus

152 )) locus (HTR2A), previously associated with psychotropic medication treatment outcome.

153 t a major issue is the potential confound of psychotropic medication upon experimental measures.

154 telligence quotient and after accounting for psychotropic medication usage and comorbid psychopatholo

155 This study examined patterns of psychotropic medication use after the Sept. 11, 2001, te

156 Depression and psychotropic medication use are potential risk indicator

157 y mental disorders during the 3 prior years, psychotropic medication use during the prior year, and i

158 ffects on decreasing behavioral symptoms and psychotropic medication use in dementia residents in lon

159 Psychotropic medication use in the past 12 months.

160 mine the association of mental disorders and psychotropic medication use with osteoporotic fracture r

161 for major depressive disorder, were free of psychotropic medication use, and had a baseline 17-item

162 ma exposure, lifetime psychiatric diagnoses, psychotropic medication use, FKBP5 rs1360780 genotype, F

163 over time by provider specialty, concomitant psychotropic medication use, number of annual visits, an

164 were not affected by non-BD psychopathology, psychotropic medication use, or symptomatology.

165 ore rapidly and has coincided with increased psychotropic medication use.

166 iagnoses, conventional CVD risk factors, and psychotropic medication use.

167 Psychotropic medication visits increased at comparable r

168 ortion of mental health outpatients received psychotropic medication without psychotherapy.

169 human resources, rehabilitation facilities, psychotropic medication, and community mental health as

170 rimary care physicians prescribe concomitant psychotropic medication, and they show great variability

171 using mental health services (talk therapy, psychotropic medication, and/or a support group), most c

172 diagnosis of MDD, not currently treated with psychotropic medication, between ages of 18 and 65 (mean

173 ng participants who did not voluntarily take psychotropic medication, even minor assaultiveness was a

174 lth conditions with only psychotherapy, only psychotropic medication, or their combination; the mean

175 c treatment lasted 6 months and consisted of psychotropic medication, psychoeducation, and brief supp

176 a clinical research facility completed by 75 psychotropic medication-free patients with remitted MDD

177 pression is associated with being prescribed psychotropic medication.

178 ic disorder, current depression, and current psychotropic medication.

179 None was taking psychotropic medication.

180 tment are most likely to receive concomitant psychotropic medication.

181 sychiatric facilities were given concomitant psychotropic medication.

182 n antipsychotic drug treatment with a second psychotropic medication.

183 nces were found in patients currently taking psychotropic medication.

184 present whether or not the participant takes psychotropic medication.

185 e the likelihood of off-label prescribing of psychotropic medication.

186 Outpatient mental health treatment and psychotropic-medication use in children and adolescents

187 der (22.5% vs 5.8%; P = .005), and receiving psychotropic medications (18.0% vs 4.7%; P = .007), intr

188 ds with or without dispensed prescription of psychotropic medications (antipsychotics, antidepressant

189 use of psychotherapy (from 4.2% to 6.0%) and psychotropic medications (from 5.5% to 8.9%), including

190 health diagnoses (P = 0.019) and the use of psychotropic medications (P = 0.015) were significantly

191 e of the most commonly prescribed classes of psychotropic medications among US youths.

192 -SSRI antidepressants, and nonantidepressant psychotropic medications and analyses in the clinically

193 riod of expansion in the number of available psychotropic medications and growth in managed behaviora

194 Before treatment, all subjects were free of psychotropic medications and had a score </=20 on the Ce

195 Maintenance psychotropic medications and supportive psychotherapy we

196 te the associations between major classes of psychotropic medications and violent reoffending.

197 information on mental health service use and psychotropic medications are scarce.

198 , most patients in these studies were taking psychotropic medications at the time of PPI testing, and

199 ed a psychiatric diagnosis or treatment with psychotropic medications by ages 16-17.

200 scribes the prevalence and pattern of use of psychotropic medications by HIV-positive patients receiv

201 predict mental health service use and use of psychotropic medications during adolescence.

202 ionship, such as genetic factors, the use of psychotropic medications during pregnancy, the timing wi

203 U.S. prescriptions (156.9 million claims for psychotropic medications during the study period) and a

204 Recent reports on the use of psychotropic medications for preschool-aged children wit

205 Although mortality related to psychotropic medications has received much attention in

206 Many other psychotropic medications have been considered and used t

207 stimated 27.2% of HIV-positive patients took psychotropic medications in 1996.

208 e 1955 was conducted to determine the use of psychotropic medications in breast-feeding women.

209 No controlled studies on the safety of psychotropic medications in nursing mothers were found.

210 over widespread overmedication and misuse of psychotropic medications in US youth.

211 Combining psychotropic medications is common for people diagnosed

212 Rapid discontinuation of some psychotropic medications is followed by discontinuation

213 Finally, the use of psychotropic medications is not unusual in personality d

214 Numerous other psychotropic medications may be considered, alone or in

215 Treatment with psychotropic medications may contribute to obesity in wa

216 Many psychotropic medications must be considered when treatin

217 ignificant effect or ameliorative effects of psychotropic medications on abnormal structural and func

218 linical studies have demonstrated effects of psychotropic medications on PPI.

219 er Lhx6 mRNA levels were not attributable to psychotropic medications or illness chronicity.

220 These differences were not attributable to psychotropic medications or other comorbid factors.

221 There was an increase in the number of psychotropic medications prescribed across years; visits

222 In all 3 data sources, psychotropic medications prescribed for preschoolers inc

223 compared NAVIGATE and community care on the psychotropic medications prescribed, side effects experi

224 small case series for each of the different psychotropic medications serve as the basis for suggeste

225 Most of the evidence on other psychotropic medications such as antidepressants, mood s

226 Psychotropic medications target glycogen synthase kinase

227 nt mental health services, and on prescribed psychotropic medications through ages 16-17.

228 Diagnostic Interview and a questionnaire on psychotropic medications used during the previous 6 mont

229 nd adjusted costs for services and dispensed psychotropic medications were calculated.

230 Psychotropic medications were discontinued before random

231 6 months, and who were free of hormonal and psychotropic medications were recruited into 4 study gro

232 ntly face the need to decide whether to take psychotropic medications while breast-feeding.

233 essant without a clear indication, 10.1% for psychotropic medications without an antipsychotic, and 1

234 total brain volume, age, gender, education, psychotropic medications, alcohol use, and race/ethnicit

235 er involvement of physicians, greater use of psychotropic medications, and expanding availability of

236 antiarrhythmic agents, antimicrobial drugs, psychotropic medications, and methadone, as well as a gr

237 12-month mental disorder had been prescribed psychotropic medications, and most had evidence of psych

238 otic or manic symptoms, no use of concurrent psychotropic medications, and no current dependence on i

239 f comorbid major depressive disorder, use of psychotropic medications, assay used, and time of day bl

240 Despite evidence of the increasing use of psychotropic medications, little is known about the broa

241 All subjects were free of alcohol, psychotropic medications, or drugs of abuse.

242 ases in the use of and costs associated with psychotropic medications, particularly for youths with m

243 n mental disorder diagnoses, prescription of psychotropic medications, provision of psychotherapy, or

244 milar patterns were found for treatment with psychotropic medications.

245 ht also exhibit changes after treatment with psychotropic medications.

246 nstrated following administration of several psychotropic medications.

247 ation services, neurologic events, or use of psychotropic medications.

248 were not using any mental health services or psychotropic medications.

249 of individuals with dose increases in their psychotropic medications.

250 ied by a commensurate increase in the use of psychotropic medications.

251 tions, new prescriptions, or daily doses for psychotropic medications.

252 and increased public acceptance of effective psychotropic medications.

253 e course of 10 years to examine their use of psychotropic medications.

254 treatment for weight gain in patients taking psychotropic medications.

255 physicians and provided in conjunction with psychotropic medications.

256 milar regions of the brain, or the effect of psychotropic medications.

257 ohol abuse or dependence, and current use of psychotropic medications.

258 antidepressants, or other nonantidepressant psychotropic medications.

259 ithout mental disorders and those not taking psychotropic medications.

260 actures based on mental disorders and use of psychotropic medications.

261 articipants were weight-restored and free of psychotropic medications.

262 K3beta activity contributes to the action of psychotropic medications.

263 pulation or among control groups using other psychotropic medications.

264 Adjustments were made for other psychotropic medications.

265 health systems might improve availability of psychotropic medicines and that overall country developm

266 While access to psychotropic medicines varies substantially across count

267 Availability of psychotropic medicines was associated with features of a

268 e interventions, including administration of psychotropic medicines, the number of persons who remain

269 systems components associated with access to psychotropic medicines.

270 an produce proteases: among them, those from psychotropic microorganisms (e.g. Bacillus subtilis), wh

271 etylhomotaurinate by itself is not an active psychotropic molecule.

272 al profiling revealed conserved functions of psychotropic molecules and predicted the mechanisms of a

273 le in animal models of FXS and assessment of psychotropic monotherapy on ERK activation.

274 sonance imaging studies were conducted in 22 psychotropic-naive patients with MDD, aged 9 to 17 years

275 regnant women, 10% received opioids only, 6% psychotropics only, and 2% opioids with coprescription o

276 with coprescription versus those prescribed psychotropics only.

277 related to depression symptoms, medications (psychotropics), or failure to perceive/appreciate the ne

278 aapi is the basic ingredient of ayahuasca, a psychotropic plant tea used in the Amazon for ritual and

279 receptors serve as molecular targets for the psychotropic plant-derived cannabis constituent Delta(9)

280 The increasing trend of psychotropic polypharmacy was mostly similar across visi

281 e analyzed to examine patterns and trends in psychotropic polypharmacy within nationally representati

282 in 2004 and 2009 on antipsychotic and other psychotropic prescribing.

283 From 2001 to 2015, psychotropic prescription overall increased from 4.4% to

284 er adjustment for age, gender, number of non-psychotropic prescriptions 6 months before the cancer de

285 Opioid and psychotropic prescriptions are common during pregnancy.

286 ization (e.g., medication management visits, psychotropic prescriptions, and mental health/substance

287 t no significant increase in the rate of new psychotropic prescriptions.

288 ple) who might benefit from changes in their psychotropic prescriptions.

289 rders, inflammation, and pain while avoiding psychotropic side effects mediated by CB1.

290 h CBD may counteract the psychotomimetic and psychotropic side effects of THC.SIGNIFICANCE STATEMENT

291 y should not cross the BBB to avoid possible psychotropic side effects.

292 ated by the need to avoid cardiovascular and psychotropic side effects.

293 Exclusion criteria were the use of illicit psychotropic substances, mental confusion, hepatic encep

294 Cannabidiol (CBD), the non-psychotropic therapeutically active ingredient of Cannab

295 Psychotropic treatment has been frequently associated wi

296 Psychotropic treatments included antipsychotics for schi

297 ges in CRMPs levels have been observed after psychotropic treatments, and disrupting CRMP2 binding to

298 We observed disparities in nonopioid psychotropic use between black and white women (adjusted

299 escription was higher among women prescribed psychotropics versus those who were not (26.5% vs. 10.7%

300 Psychotropics were commonly used by HIV-positive patient